<DOC>
	<DOCNO>NCT01982175</DOCNO>
	<brief_summary>This phase II , prospective , multicenter , open-label study evaluate efficacy safety Alemtuzumab patient relapse refractory B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Phase II Clinical Trial Alemtuzumab Treat B-cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>An establish diagnosis Bcell chronic lymphocytic leukemia ( BCLL ) Meet criterion relapse refractory CLL Presence one measurable lesion ECOG Score 01 Life expectancy &gt; 3 month Female patient childbearing potential must negative serum pregnancy test , male female patient must agree use effective contraceptive method study treatment , minimum 1 year follow study therapy . Less 2 week prior anticancer therapy . Allergic antibody component investigational product . Other severe , concurrent disease , include mental disorder , serious cardiac functional capacity ( Class III IV ) , uncontrolled diabetes . Use investigational agent rather Alemtuzumab . Active systematic infection major organ malfunction require treatment . Serum total bilirubin great equal 1.5 time upper limit normal ; Serum alanine aminotransferase ( ALT ) and/or serum aspartate aminotransferase ( AST ) great equal 2.5 time upper limit normal ( liver metastasis ) ; ALT and/or AST great equal 5 time upper limit normal ( liver metastasis ) . Blood urea nitrogen ( BUN ) great equal 1.5 time upper limit normal Serum creatinine great equal 1.5 time upper limit normal . White blood cell ( WBC ) count &lt; 3.5×109/L Absolute neutrophil count ( ANC ) &lt; 1.5×109/L platelet count &lt; 75×109/L Hemoglobin &lt; 80g/L . Human immunodeficiency virus ( HIV ) positive . Active hepatitis history prior viral hepatitis B C , positive hepatitis B serology without prior immunization . Pregnant nursing woman . Known central nervous system ( CNS ) metastases BCLL . Active secondary malignancy . cytomegalovirus ( CMV ) positive immunodeficiency disease stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>CD52</keyword>
</DOC>